• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Microbiol . Performance characteristics of a high throughput automated transcription mediated amplification test for SARS-CoV-2 detection

tetano

Editor, Senior Moderator
J Clin Microbiol


. 2020 Jul 29;JCM.01669-20.
doi: 10.1128/JCM.01669-20. Online ahead of print.
Performance characteristics of a high throughput automated transcription mediated amplification test for SARS-CoV-2 detection


Jimmykim Pham[SUP] 1 [/SUP], Sarah Meyer[SUP] 1 [/SUP], Catherine Nguyen[SUP] 1 [/SUP], Analee Williams[SUP] 1 [/SUP], Melissa Hunsicker[SUP] 1 [/SUP], Ian McHardy[SUP] 2 [/SUP], Inessa Gendlina[SUP] 3 [/SUP], D Yitzchak Goldstein[SUP] 3 [/SUP], Amy S Fox[SUP] 3 [/SUP], Angela Hudson[SUP] 1 [/SUP], Paul Darby[SUP] 1 [/SUP], Paul Hovey[SUP] 1 [/SUP], Jose Morales[SUP] 1 [/SUP], James Mitchell[SUP] 1 [/SUP], Karen Harrington[SUP] 1 [/SUP], Mehrdad Majlessi[SUP] 1 [/SUP], Joshua Moberly[SUP] 1 [/SUP], Ankur Shah[SUP] 1 [/SUP], Andrew Worlock[SUP] 1 [/SUP], Marion Walcher[SUP] 1 [/SUP], Barbara Eaton[SUP] 1 [/SUP], Damon Getman[SUP] 4 [/SUP], Craig Clark[SUP] 1 [/SUP]



Affiliations

Abstract

The COVID-19 pandemic caused by the new SARS-CoV-2 coronavirus has imposed severe challenges on laboratories in their effort to achieve sufficient diagnostic testing capability for identifying infected individuals. In this study we report the analytical and clinical performance characteristics of a new, high-throughput, fully automated nucleic acid amplification test system for the detection of SARS-CoV-2. The assay utilizes target capture, transcription mediated amplification, and acridinium ester-labeled probe chemistry on the automated Panther System to directly amplify and detect two separate target sequences in the ORF1ab region of the SARS-CoV-2 RNA genome. The probit 95% limit of detection of the assay was determined to be 0.004 TCID[SUB]50[/SUB]/ml using inactivated virus, and 25 c/ml using synthetic in vitro transcript RNA targets. Analytical sensitivity (100% detection) was confirmed to be 83 - 194 c/ml using three commercially available SARS-CoV-2 nucleic acid controls. No cross reactivity or interference was observed with testing six related human coronaviruses, as well as 24 other viral, fungal, and bacterial pathogens, at high titer. Clinical nasopharyngeal swab specimen testing (N=140) showed 100%, 98.7%, and 99.3% positive, negative, and overall agreement, respectively, with a validated reverse transcription PCR NAAT for SARS-CoV-2 RNA. These results provide validation evidence for a sensitive and specific method for pandemic-scale automated molecular diagnostic testing for SARS-CoV-2.
 
Back
Top Bottom